FDA accepts AstraZeneca's new drug application
19th Nov 2013 07:37
AstraZeneca said the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for naloxegol, which is used for the treatment of opioid-induced constipation (OIC). The company filed the NDA after completing the Phase III KODIAC programme, which included four clinical trials
Read moreFriday broker round-up UPDATE
15th Nov 2013 07:38
Amlin: Berenberg raises target price from 398p to 434p, but still recommends selling. Barclays cuts target price from 481p to 453p and retains an overweight rating. Antofagasta: Numis raises target price from 750p to 850p and reiterates a hold recommendation. AstraZeneca: Liberum Capital upgrades
Read moreWednesday broker round-up
13th Nov 2013 12:33
AMEC: Credit Suisse downgrades from outperform to neutral with a target price of 1250p. Antofagasta: Alphavalue lowers target price from 1000.6p to 999.5p, while upgrading from add to buy. Associated British Foods: Credit Suisse raises target price from 1850p to 2250p and keeps a neutral rating.
Read moreMonday broker round-up UPDATE
4th Nov 2013 08:07
Aggreko: Cantor Fitzgerald reduces target price from 2200p to 1700p downgrading to hold. Anglo American: Alphavalue upgrades from add to buy with a target price of 1801.3p. APR Energy: Cantor Fitzgerald raises target price from 670p to 1000p, but still recommends selling. Astra Zeneca: UBS reduce
Read moreAdvanced Computer Software Chairman trades in 1m shares
1st Nov 2013 16:08
The Chairman of Advanced Computer Software this week sliced off 870,380 pounds-worth of shares from his stake, reducing it to 2.42m, the group announced after the close on Thursday. Michael Jackson disposed of exactly 1m shares in the healthcare and business management software, and said he made t
Read moreFTSE 100 movers: BT jumps after impressing with Sport package
31st Oct 2013 13:26
Telecomms heavyweight BT today reported a 13 per cent decline in half-year pre-tax profits to 948m pounds, but said the recently introduced BT Sport package had made a 'confident start'. Shares in the group floated higher, encouraged by a 13 per cent jump in the interim dividend to 3.4p and a reaffi
Read moreBroker snap: AstraZeneca a 'hold' after Q3 results, says Panmure
31st Oct 2013 11:43
AstraZeneca's shares fell on Thursday after it reported third quarter results that fell short of consensus, but broker Panmure Gordon recommended the shares be held. Revenues were down 4% to $6.2bn due to the impact from products with loss of patent protection on key drugs. It compared to the $6.38
Read moreLondon open: FTSE swoops lower, dragged by Croda Intl
31st Oct 2013 08:45
- FTSE led lower by Croda Intl - Guidance sought from abroad - German consumer confidence falls techMARK 2,646.30 -0.70% FTSE 100 6,753.63 -0.36% FTSE 250 15,493.32 -0.58% The FTSE offered up few treats on Thursday, swooping 24 points lower in early trade, following the Federal Open Market Committ
Read moreAstrazeneca appoints new CFO as third quarter revenues fall - UPDATE
31st Oct 2013 07:26
- New CFO appointed - Revenues and profits fall in Q3 - Court trial over Pulmicort Respules patent continues AstraZeneca announced the appointment of Marc Dunoyer as Chief Financial Officer as it reported a fall in third quarter revenue. Dunoyer, currently Executive Vice President, Global Portfol
Read moreAstrazeneca begins third phase of asthma study
30th Oct 2013 07:54
- Phase III of Windward begins - Developing treatment for uncontrolled asthma Drugs giant AstraZeneca has started the third phase of the Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company's global biologics research and dev
Read moreLondon close: FTSE ends higher after UK data
28th Oct 2013 16:30
- FTSE closes modestly higher - Investors pause ahead of tomorrow's Fed meeting - Aggreko leads risers, Tullow is biggest faller techMARK 2,640.77 +0.06% FTSE 100 6,725.82 +0.07% FTSE 250 15,428.79 -0.41% The FTSE ultimately ended the session higher, albeit marginally, tracking some modest gains o
Read moreFTSE 100 movers: Aggreko tops leaders on full-year expectations
28th Oct 2013 14:44
Temporary power group Aggreko climbed into the top spot after it said it expected full year profits to be in line with market expectations despite the absence of a one-off lift from the London Olympics. Also on the rise was Randgold Resources after boss Mark Bristow said the miner is exploring furt
Read moreMonday broker round-up UPDATE
28th Oct 2013 08:55
Admiral Group: Numis raises target price from 1170p to 1425p upgrading to add. Aggreko: Investec places its target price (prev.: 1700p) under review and retains a hold recommendation. WH Ireland reduces target price from 2050p to 1700p downgrading from buy to outperform. Panmure Gordon reduces targ
Read moreLondon close: Markets lifted by corporate earnings, China outlook
24th Oct 2013 16:22
- FTSE 100 at levels not seen since May - China manufacturing PMI at seven-month high - Financials, miners and pharma stocks gain techMARK 2,642.27 +0.68% FTSE 100 6,713.18 +0.58% FTSE 250 15,526.93 +0.21% UK markets set a fresh five-month high on Thursday as investors celebrated an improved outlo
Read moreSector movers: Shire gives pharma sector a boost after Q3 beat
24th Oct 2013 15:31
Strong results from Shire injected some gains into the pharmaceuticals sector on Thursday after the company beat quarterly forecasts and hiked its guidance for the full year. The FTSE 100 specialty biopharmaceuticals stock was up an impressive 8.4% at 2,737p in afternoon trade following its results
Read more